Zibotentan and Dapagliflozin combination, EvAluated in Liver cirrhosis (ZEAL study)

Trial Identifier: D4326C00003
Sponsor: AstraZeneca
Start Date: October 2022
Primary Completion Date: May 2025
Study Completion Date: July 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AT Wien, AT, 1090
AU Heidelberg, AU, 3084
BE Edegem, BE, 2650
CH Bern, CH, 3010
CH Lugano, CH, 6900
CH Luzern, CH, 6000
CN Beijing, CN, 100057
CN Chengdu, CN, 610000
CN Guangzhou, CN, 510515
CN Hangzhou, CN, 310000
CZ Praha, CZ, 128 00
CZ Praha, CZ, 169 02
DE Dresden, DE, 01307
DE Landshut, DE, 84034
DE Mainz, DE, 55131
DE Münster, DE, 48149
DE Wiesbaden, DE, 65189
DK Aarhus N, DK, 8200
DK Esbjerg, DK, 6700
DK Hvidovre, DK, 2650
DK Køge, DK, 4600
ES Barcelona, ES, 08036
ES Barcelona, ES, 08041
ES Barcelona, ES, 08035
ES Madrid, ES, 28034
ES Madrid, ES, 28007
ES Majadahonda, ES, 28222
ES Santander, ES, 39008
FR ANGERS Cedex 9, FR, 49933
FR Clichy, FR, 92110
FR Paris Cedex 13, FR, 75651
FR Toulouse, FR, 31059
GB Birmingham, GB, B9 5SS
GB Cambridge, GB, CB2 0XY
GB London, GB, SE5 9RS
NL Amsterdam, NL, 1081 HV
RO Cluj-Napoca, RO, 400162
TW Taipei, TW, 112
TW Taipei, TW, 10002
US, AL Birmingham, AL, US, 35233
US, CA Pasadena, CA, US, 91105
US, CA San Francisco, CA, US, 94115
US, CA West Hollywood, CA, US, 90048
US, MN Rochester, MN, US, 55905
US, NY Bronx, NY, US, 10467
US, SC Charleston, SC, US, 29425
US, TX Dallas, TX, US, 75246
US, VA Charlottesville, VA, US, 22903
US, VA Richmond, VA, US, 23249
US, WI Milwaukee, WI, US, 53226